Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jan 30;16(4):578–590. doi: 10.1158/1535-7163.MCT-16-0606

Figure 2. HJC0152 reduces the invasiveness of HNSCC cells in vitro.

Figure 2

(A) A Transwell assay showed that HJC0152 dramatically attenuated the migration (without Matrigel) and invasion capacity (with Matrigel) of SCC25 and CAL27 cells. Cells were seeded in the top compartment of a Transwell chamber and left untreated (Control) or treated with DMSO or HJC0152 for 24 h (P < 0.05, Scale bar, 100 μm). (B, C) SCC25 and CAL27 cells were treated with HJC0152 for 24 h, and the expression of EMT-related proteins was analyzed by both Western blot and immunofluorescence. * P < 0.05, *** P < 0.001.